Novatti Group Ltd. Announces Successful Seed Round Closure for AUDC

On August 14, 2025, Novatti Group Ltd. (ASX: NOV), a leading fintech company based in Melbourne, Australia, announced that its majority-owned subsidiary, AUDC Pty Ltd (AUDC), has successfully closed a Seed equity capital raising. The round attracted A$1.2 million in new investment, with shares issued at A$0.35 per share. This successful closure brings AUDC’s total raised capital to over A$2 million.

Key Highlights:

  • Investment Details: AUDC raised A$1.2 million at A$0.35 per share during the Seed Round.
  • Novatti’s Stake: Novatti holds a 57% interest in AUDC, retaining 20 million shares valued at A$7 million. The company has no obligation to contribute additional capital.
  • Business Expansion: AUDC’s business continues to expand, driven by growth in stablecoin issuance, institutional partnerships, and on-chain transaction volumes.
  • Market Trends: The global trends, including Circle’s IPO and the GENIUS Act in the US, highlight the accelerating market and regulatory endorsement of stablecoins.
  • Project Acacia: AUDD, a digital settlement asset, has been selected for pilot use by Australia’s national payments platform, AP+, in “Project Acacia.”

Novatti Group Ltd., which specializes in providing software and payment solutions, particularly for consumer digital wallets, branchless banking, mobile money, bill payments, and voucher management systems, as well as utility billing and payment services, continues to strengthen its position in the fintech sector. The company serves its customers in Australia and the United Kingdom.

Company Overview:

  • Sector: Information Technology
  • Industry: Software
  • Primary Exchange: ASX All Markets
  • Currency: AUD
  • Close Price (2025-08-12): 0.03 AUD
  • 52 Weeks High (2024-09-22): 0.091 AUD
  • 52 Weeks Low (2025-07-01): 0.019 AUD
  • Market Cap: 16,799,951 AUD

For more information about Novatti Group Ltd. and its offerings, visit their website at www.novattigroup.com .

Swiss Ministers Meet with Pharma Executives Amid Tariff Uncertainty

On August 14, 2025, Swiss ministers met with senior executives of pharmaceutical companies Roche (ROG.S) and Novartis (NOVN.S) to discuss the outlook for the sector under current U.S. trade policy. The meeting comes amid uncertainty following President Donald Trump’s imposition of U.S. import tariffs of 39% on Swiss goods, one of the highest rates worldwide. Although pharmaceutical firms have so far been spared the duties, the Trump administration is carrying out a probe into pharmaceutical imports, which could lead to tariffs.

Swiss Interior Minister Elisabeth Baume-Schneider and Economy Minister Guy Parmelin met with Roche Chairman Severin Schwan and Patrick Horber, head of the international unit for Novartis. The participants exchanged views on the current situation in the pharmaceutical industry against the backdrop of discussions about the tariffs imposed by the United States. The details of the discussion remain confidential.

Vanguard Health Care Fund’s Strategic Moves: Johnson & Johnson Takes Center Stage

On August 14, 2025, the Vanguard Health Care Fund highlighted Johnson & Johnson (JNJ) as a key focus in its strategic moves. The fund’s stock picks include other notable companies such as LLY, LSE:AZN, UNH, MRK, BSX, GILD, ELV, COR, BPMC, and SGRY. The fund’s strategy emphasizes the importance of Johnson & Johnson in its portfolio, reflecting the company’s significant role in the healthcare sector.

For more information on the Vanguard Health Care Fund’s stock picks and strategic moves, visit www.reuters.com .